Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

The term ferroptosis was put forward in 2012 and has been researched exponentially over
the past few years. Ferroptosis is an unconventional pattern of iron-dependent programmed …

PD-L1 is an immunoinhibitory molecule that suppresses the activation of T cells, leading to
the progression of tumors. Overexpression of PD-L1 in cancers such as gastric cancer …

Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic
cancer therapies. Identifying factors predicting clinical response could guide patient …

Glioblastoma (GBM) is the most common, and aggressive, primary brain tumor in adults.
With a median patient survival of less than two years, GBM represents one of the biggest …

Colorectal cancer (CRC), as a prominent cause of cancer-related deaths, has historically
been notable worldwide and many attempts have been made to raise the overall survival of …

Introduction Epidermal growth factor receptor (EGFR) mutation status was reported to be
associated with programmed death-ligand 1 (PD-L1) expression. However, the molecular …

Expression of programmed cell death receptor ligand 1 (PDL1) has been scarcely studied in
breast cancer. Recently PD1/PDL1-inhibitors have shown promising results in different …

Recent strategies targeting the interaction of the programmed cell death ligand-1 (PD-L1, B7-
H1, CD274) with its receptor, PD-1, resulted in promising activity in early phase clinical trials …

Cancer cells expressing PD-1 ligands (PD-L1/PD-L2) inhibit immune-modulatory T-cell
activation facilitating disease progression. Preliminary clinical trials exploring interruption of …